Viromed Medical AG, a medical technology company specializing in cold plasma technology, has completed its transition from bearer shares to registered shares following a resolution approved at its Annual General Meeting on July 29, 2025. The conversion, which became effective after entry into the commercial register on August 8, 2025, represents a strategic shift in how the company manages its shareholder relationships and corporate governance structure.
The technical conversion process occurred on the evening of January 16, 2026, when all 21,250,000 bearer shares previously held under ISIN DE000A3MQR65 were deregistered by custodian banks and Clearstream Banking AG in Frankfurt. Shareholders received one new registered share for each previous bearer share, with each share representing €1.00 of share capital under the new ISIN DE000A40VZN7. The company has excluded the right to individual certification, instead maintaining a global certificate deposited with Clearstream Banking AG.
This transition carries significant implications for shareholder transparency and corporate communication. Registered shares enable the company to maintain a direct, up-to-date register of shareholders, facilitating more targeted communication and engagement. Unlike bearer shares, where ownership remains anonymous through financial intermediaries, registered shares create a direct relationship between the company and its investors. This aligns with broader trends in corporate governance emphasizing transparency and shareholder rights.
Trading continuity was maintained throughout the transition, with the final trading day for bearer shares occurring on January 14, 2026, and the new registered shares commencing trading under the new ISIN on January 15, 2026. Importantly, the conversion does not affect shareholders' proportional ownership or associated rights, nor does it restrict their ability to sell shares, as transfer of registered shares does not require company approval.
The move holds particular relevance for Viromed Medical AG's growth trajectory in the medical technology sector. As a company listed since October 2022 and focused on advancing cold plasma technology through its subsidiary Viromed Medical GmbH, enhanced shareholder communication could support its expansion goals in the DACH region and beyond. The company's website, https://www.viromed-medical-ag.de, provides additional corporate information, while the original announcement appeared on https://www.newmediawire.com.
For investors, this transition reduces administrative layers between ownership and corporate governance, potentially enabling more responsive shareholder relations. In an industry where innovation and regulatory compliance are paramount, direct communication channels could prove valuable for conveying complex medical technology developments and growth strategies. The conversion represents both a technical corporate action and a strategic commitment to transparent investor relations as the company pursues its stated goal of advancing cold plasma technology in medical applications.
